CR20120617A - COMBINATION OF XANTNA OXIDASA INHIBITORS AND ANTIGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE - Google Patents

COMBINATION OF XANTNA OXIDASA INHIBITORS AND ANTIGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE

Info

Publication number
CR20120617A
CR20120617A CR20120617A CR20120617A CR20120617A CR 20120617 A CR20120617 A CR 20120617A CR 20120617 A CR20120617 A CR 20120617A CR 20120617 A CR20120617 A CR 20120617A CR 20120617 A CR20120617 A CR 20120617A
Authority
CR
Costa Rica
Prior art keywords
angiotensin
combination
receptor
xantna
oxidasa
Prior art date
Application number
CR20120617A
Other languages
Spanish (es)
Inventor
Francesco Melani
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of CR20120617A publication Critical patent/CR20120617A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una combinación de principios activos, a saber de un inhibidor de xantina oxidasa con uno o más antagonistas del receptor de angiotensina II, composiciones farmacéuticas que contienen a dichos principios activos, para uso en el tratamiento terapéutico humano o veterinario; y métodos para su preparación.The present invention relates to a combination of active principles, namely a xanthine oxidase inhibitor with one or more angiotensin II receptor antagonists, pharmaceutical compositions containing said active principles, for use in human or veterinary therapeutic treatment; and methods for its preparation.

CR20120617A 2010-05-10 2012-12-06 COMBINATION OF XANTNA OXIDASA INHIBITORS AND ANTIGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE CR20120617A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000233A IT1400609B1 (en) 2010-05-10 2010-05-10 ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND METFORMIN AND THEIR USE.

Publications (1)

Publication Number Publication Date
CR20120617A true CR20120617A (en) 2013-03-04

Family

ID=43519819

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120617A CR20120617A (en) 2010-05-10 2012-12-06 COMBINATION OF XANTNA OXIDASA INHIBITORS AND ANTIGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE

Country Status (5)

Country Link
AR (1) AR081024A1 (en)
CR (1) CR20120617A (en)
IT (1) IT1400609B1 (en)
TW (1) TW201206431A (en)
WO (1) WO2011141419A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033705A1 (en) * 2022-08-08 2024-02-15 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (en) 1990-11-30 1992-06-11 Teijin Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
PT1956014T (en) 1998-06-19 2019-04-24 Teijin Pharma Ltd Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
CA2617248C (en) 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
BRPI0718611A2 (en) 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc METHODS FOR PRESERVING RENAL FUNCTION USING XANTINE OXIDOREDUTASE INHIBITORS.
US20100305074A1 (en) * 2007-04-04 2010-12-02 Hight H Thomas Niacin-based pharmaceutical compositions
WO2008147601A1 (en) * 2007-04-17 2008-12-04 University Of Florida Research Foundation, Inc. Methods and compositions for ameliorating thiazide induced hyperlipidemia

Also Published As

Publication number Publication date
AR081024A1 (en) 2012-05-30
ITRM20100233A1 (en) 2011-11-11
WO2011141419A1 (en) 2011-11-17
IT1400609B1 (en) 2013-06-14
TW201206431A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
ECSP11011459A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
CL2013001338A1 (en) Compounds derived from substituted benzothiene-pyridines, hiv replication inhibitors; pharmaceutical composition that includes them; pharmaceutical combination; pharmaceutical kit; and its use for the treatment of hiv.
ECSP11011327A (en) AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, AND THEIR USES IN THERAPY
CL2013000016A1 (en) Compounds derived from imidazopyridine; preparation procedure; Pharmaceutical composition and its use in the treatment of cancer.
EA201200550A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING BI-1356 AND METFORMIN
CL2013003547A1 (en) Peptide derived from oxintomodulin; polynucleotide that encodes it; pharmaceutical composition that includes it; use of the peptide to treat obesity.
CL2012002189A1 (en) Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors.
CL2012002356A1 (en) Heterocyclic acid compounds derived from bisyl-linked aryltriazolones, vasopressin receptor inhibitors v1a and v2; preparation procedure; pharmaceutical composition; and its use to treat and / or prevent acute and chronic heart failure, hyponatremia, among others.
CO6400170A2 (en) AGOSNISTS AND ANTAGONISTS OF THE S1P5 RECEIVER AND METHODS OF USE OF THE SAME
CL2012003745A1 (en) Compounds derived from aminopyrazoloquinazolines, as inhibitors against the phosphorylating activity of the igf-1 receptor located in cell membranes; pharmaceutical preparation that contains them; and its use in the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
EA201170940A1 (en) CANCER TREATMENT USING BENDAMUSTIN AND ANTI-CD20-ANTIBODY COMBINATION
CL2011000214A1 (en) Pharmaceutical composition comprising micronized progesterone and type II safflower oil; and use for the treatment of a condition related to insufficient progesterone secretion.
UY33530A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES
MX2019008817A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof.
UY32520A (en) COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
CL2009001841A1 (en) Use of a sustained release composition of 4-aminopyridine to prepare a medicament useful for treating multiple sclerosis in a subject.
ECSP12012331A (en) COMBINATION OF XANTINA OXIDASE INHIBITORS AND ANTAGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE
CR20120617A (en) COMBINATION OF XANTNA OXIDASA INHIBITORS AND ANTIGONISTS OF THE ANGIOTENSIN II RECEPTOR AND ITS USE
CR20120461A (en) HYDROBROMIDE HYDROBROMIDE HYDROBROMIDE AND PREPARATION OF THIS
BR112013004714A2 (en) "combinations of hdac inhibitors with thrombocytopenia drugs and their uses"
CL2012000355A1 (en) Compounds derived from 4-amino-butenamide; pharmaceutical composition; and use in the treatment of COPD.
TR201102857A2 (en) Pharmaceutical formulations of telmisartan and diuretic combination.
CO6630144A2 (en) Association of xanthine oxidase and instatin inhibitors and their use
CL2009001327A1 (en) Heterocycle compounds derived from 3-oxoisoindoline-1-carboxamide; pharmaceutical composition comprising said compounds; and use in the treatment of pain.